Sign In
Last checked at 
1 Apr 2026 07:00
1 April 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Block Listing Return
The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
Name of applicant: | Cambridge Cognition Holdings plc | |||
Name of scheme: | Share Options | |||
Period of return: | From: | 1 October 2025 | To: | 31 March 2026 |
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023 | |||
Balance of unallotted securities under scheme(s) from previous return: | 466,316 ordinary shares | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period: | Nil | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 466,316 ordinary shares | |||
Name of contact: | Simon McKeating |
Telephone number of contact: | +44 (0)1223 810700 |
Enquiries:
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer Adam Michael, Head of Corporate Communications | Tel: +44 1223 810700 press@camcog.com |
Panmure Liberum Limited (NOMAD & Joint Broker) Will Goode / Mark Rogers / Freddy Crossley Rupert Dearden | Tel: +44 20 7886 2968 (Corporate Finance) (Corporate Broking) |
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram | Tel: +44 20 7496 3000
|
ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.
The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands. These assessments are designed to:
● require minimal specialist administration
● deliver objective results in real time or shortly after completion
● reduce administrator bias
● support longitudinal monitoring of cognitive function
Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.
CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:
● CANTAB One™ - a brief assessment of overall cognitive function
● CANTAB Insight™ - a three-task battery providing deeper insight across five cognitive sub-domains
● CANTAB Plus™ - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias
For further information, visit: www.cambridgecognition.com
Follow the stocks
